Phase 2
It was, as usual, a pretty busy week in clinical trial news. Here’s a look.
Over the course of the past year, Novartis has seen significant success with the approval of five drugs that have blockbuster potential and the company sees an additional 25 potential blockbuster drugs in its pipeline.
Shares of France-based Ipsen are down more than 2% on the Euronext Paris exchange after the U.S. Food and Drug Administration placed a partial clinical hold on its investigational treatment for fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO).
Even with a shortened week due to the U.S. Thanksgiving holiday, there was plenty of clinical trial news and updates. Here’s a look.
Combination of Prexigebersen and Decitabine Showed Encouraging Safety and Efficacy Results
IMVT-1401, a fully human anti-FcRn antibody designed to be administered via subcutaneous injection, is the only anti-FcRn antibody known to be in clinical development for the treatment of GO
Vaccitech progresses clinical development of Universal Influenza A Vaccine (VTP-100) in Belgium and Australia and expects top-line data in early 2020
Safety and efficacy evaluation will be performed on 36 patients from 3 hospitals located in US and Australia
KidneyX seeks breakthrough solutions to transform kidney care
Frontage Clinical Services Inc. announced the implementation of ClinSpark®, a web-based eSource platform, that supports activities from subject recruitment through database lock.
PRESS RELEASES